Skip to main content Accesibility Help
×
×
Home

Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study

  • David G. Perahia (a1), Inmaculada Gilaberte (a2), Fujun Wang (a3), Curtis G. Wiltse (a3), Stacy A. Huckins (a3), Jeffrey W. Clemens (a3), Stuart A. Montgomery (a4), Angel L. Montejo (a5) and Michael J. Detke (a6)...
Abstract
Background

Relapse rates may be as high as 50% in people with major depressive disorder (MDD) previously treated to remission.

Aims

Duloxetine, an inhibitor of serotonin and noradrenaline reuptake that is licensed in Europe, the USA and elsewhere for the treatment of depressive episodes, was evaluated with regard to its efficacy, safety and tolerability in the prevention of relapse of MDD.

Method

Adult out-patients with MDD received duloxetine (60 mg daily) for 12 weeks (n=533). Patients who responded to the drug were then randomised to duloxetine (60 mgdaily) (n=136) or placebo (n=142) for 26 weeks. The primary measure of efficacy was time to relapse.

Results

Patients who received duloxetine (60 mg daily) experienced significantly longer times to relapse of MDD, and better efficacy global well-being, and quality-of-life outcomes compared with patients who received placebo. It should be noted that adverse events which occur in discontinuation may mimic some signs of depressive relapse, and were not specifically elicited in this study.

Conclusions

Duloxetine (60 mg daily) is effective in the prevention of relapse of MDD during continuation treatment.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Duloxetine in the prevention of relapse of major depressive disorder
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Duloxetine in the prevention of relapse of major depressive disorder
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Duloxetine in the prevention of relapse of major depressive disorder
      Available formats
      ×
Copyright
Corresponding author
Dr David G. Perahia, Lilly Research Centre, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK. Tel: +44 (0) 1276 483 000; fax:+44 (0) 1276 483 711; e-mail: d.perahia@lilly.com
Footnotes
Hide All

Declaration of interest

D.G.P., I.G., F.W., C.G.W., S.A.H., J.W.C. and M.J.D. are employees and stockholders of Eli Lilly and Company, Indianapolis, Indiana, USA. S.A.M. and A.L.M. have served as paid consultants for Eli Lilly and Company.

Footnotes
References
Hide All
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV): Washington, DC: APA.
Bymaster, F. P., Dreshfield-Ahmad, L. J., Threlkeld, P. G., et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 25, 871880.
DeLoach, L. J., Higgins, M. S., Caplan, A. B., et al (1998) The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesthesia and Analgesia, 86, 102106.
Detke, M. J., Lu, Y., Goldstein, D. J., et al (2002) Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. Journal of Psychiatric Research, 36, 383390.
Fava, M. (2002) Somatic symptoms, depression, and antidepressant treatment. Journal of Clinical Psychiatry, 63, 305307.
Fava, M., Schmidt, M. E., Zhang, S., et al (2002) Treatment approaches to major depressive disorder relapse. Part 2. Reinitiation of antidepressant treatment. Psychotherapy and Psychosomatics, 71, 195199.
Geddes, J. R., Carney, S. M., Davies, C., et al (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet, 361, 653661.
Greenberg, P. E., Leong, S. A., Birnbaum, H. G., et al (2003) The economic burden of depression with painful symptoms. Journal of Clinical Psychiatry, 64, 1723.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch.
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 26, 5662.
Kellner, R. A. (1987) A symptom questionnaire. Journal of Clinical Psychiatry, 48, 268274.
McKenna, S. P. & Hunt, S. M. (1992) A new measure of quality of life in depression: testing the reliability and construct validity of the QLDS. Health Policy, 22, 321330.
Hirschfeld, R. M. A. (2001) Clinical importance of long-term antidepressant treatment. British Journal of Psychiatry, 179 (suppl. 42), S4S8.
Mallinckrodt, C. H., Clark, W. S. & David, S. R. (2001) Type I error rates from mixed-effects model repeated measures compared with fixed-effects ANOVA with missing values imputed via LOCF. Drug Information Journal, 35, 12151225.
Melfi, C. A., Chawla, A. J., Croghan, T. W., et al (1998) The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Archives of General Psychiatry, 55, 11281132.
Montgomery, S. A., Rasmussen, J. G. & Tanghoj, P. (1993) A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. International Clinical Psychopharmacology, 8, 181186.
Nemeroff, C. B., Schatzberg, A. F., Goldstein, D. J., et al (2002) Duloxetine for the treatment of major depressive disorder. Psychopharmacology Bulletin, 36, 106132.
Rapaport, M. H., Bose, A. & Zheng, H. (2004) Escitalopram continuation treatment prevents relapse of depressive episodes. Journal of Clinical Psychiatry, 65, 4449.
Rosenbaum, J. F., Fava, M., Hoog, S. L., et al (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry, 44, 7787.
Schmidt, M. E., Fava, M., Zhang, S., et al (2002) Treatment approaches to major depressive disorder relapse. Part 1: Dose increase. Psychotherapy and Psychosomatics, 71, 190194.
Segal, Z., Pearson, J. & Thase, M. E. (2003) Challenges in preventing relapse in major depression. Report of a National Institute of Mental Health Workshop on state of the science of relapse prevention in major depression. Journal of Affective Disorders, 77, 97108.
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., et al (1998) The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM–IV and ICD–10. Journal of Clinical Psychiatry, 59 (suppl. 20), 2233.
Thase, M. E., Entsuah, A. R. & Rudolph, R. L. (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry, 178, 234241.
Thomas, C. M. & Morris, S. (2003) Cost of depression among adults in England in 2000. British Journal of Psychiatry, 183, 514519.
World Health Organization (1989) Pharmacotherapy of depressive disorders: consensus statement. WHO Mental Health Collaborating Centres. Journal of Affective Disorders, 17, 197198.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study

  • David G. Perahia (a1), Inmaculada Gilaberte (a2), Fujun Wang (a3), Curtis G. Wiltse (a3), Stacy A. Huckins (a3), Jeffrey W. Clemens (a3), Stuart A. Montgomery (a4), Angel L. Montejo (a5) and Michael J. Detke (a6)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *